MediPharm Labs Corp.
LABS.TO
Toronto Stock Exchange0.08
CAD
+0.01
- -
ISIN
CA58504D1006
CUSIP
58504D100
Return %
Stock
S&P500
1Y
6.67
26.53
3Y
14.29
76.60
5Y
-84.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Greg Hunter
- Full Time Employees
- 161
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 151 John Street Barrie ON Canada L4N 2L1
- IPO Date
- Mar 4, 2019
- Website
- medipharmlabs.com
- Similar Companies
- Business
- MediPharm Labs Corp. (TSX: LABS) specializes in the development, formulation, processing, packaging, and distribution of purified, pharmaceutical-grade cannabis concentrates, active pharmaceutical ingredients, and advanced cannabinoid-based derivative products utilizing Good Manufacturing Practices-certified facilities with ISO-standard cleanrooms. Founded in 2015 and headquartered at 151 John Street in Barrie, Ontario, Canada, the company operates primarily in the medical cannabis sector through wholesale, white-label, and branded platforms, serving domestic and international markets including Canada, Australia, Germany, and Brazil. Its core offerings encompass GMP cannabis API in bulk wholesale formats such as concentrates, distillates, and isolates across various cannabinoid ratios; white-label production of tinctures, soft gel capsules, vape cartridges, topicals, and custom formulations for applications in cosmetics, food and beverage, nutraceuticals, and over-the-counter or prescribed medications; and its proprietary MediPharm branded portfolio featuring high-potency oils like CBD25, CBD50, CBD100, THC30, CBN:THC 1:2, CBG:CBD 1:2, and balanced CBD:THC 20:20 in MCT or olive oil carriers, alongside soft chews, gel capsules, vape cartridges, inhalers, and dissolving drops with precise dosing in CBD, THC, CBN, and CBG profiles. The company supports clinical trials with drug-licensed materials and regulatory assistance, and maintains academic partnerships with institutions like McMaster University and Loyalist College for cannabis research. Recent developments include a landmark January 2025 commercial agreement with Brazil's Laboratório Teuto to supply full-spectrum GMP sublingual oral solutions into the $198 million medical cannabis market serving over 670,000 patients, with initial shipments pending ANVISA and Health Canada permits; the 2023 acquisition of VIVO Cannabis Inc., which expanded medical e-commerce access via Canna Farms in Canada and Beacon Medical operations in Australia and Germany while delivering revenue synergies and operating expense reductions from $40 million to half; and robust Q3 2025 financial performance with $11.4 million in revenue, up 17% year-over-year, driven by 83% growth in international medical cannabis sales.
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
MediPharm Labs Completes First Shipment to France